title: [New human vaccines].
abstract: Proteinaceous meningococcal B vaccines are under development, and the most advanced, Bexsero, is currently being evaluated by the European Medicines Agency. Approval, if granted, will be based on safety, immunogenicity, and theoretical strain coverage established in vitro. Clinical effectiveness will only be determined after market release. New, more effective influenza vaccines are also being developed. A trivalent attenuated nasal influenza vaccine (Fluenz) shows better efficacy in children than the classic trivalent seasonal inactivated vaccine, but its use is restricted to children over 2 years of age because of safety and efficacy considerations. The more potent trivalent (MF59) adjuvated inactivated influenza vaccine (Fluad), licensed for adults over 65 years of age, is being evaluated through a pediatric investigation plan. This vaccine could be useful for infants in whom unadjuvated inactivated vaccines are poorly protective, but its safety must first be fully established.
authors.affiliation: Hôpital d'enfants Armand-Trousseau, 26 avenue du Dr Arnold Netter, 75012 Paris, France. emmanuel.grimprel@trs.aphp.fr
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Grimprel
mesh_terms: D006801:Humans; D007252:Influenza Vaccines; D022401:Meningococcal Vaccines
chemical_list: D007252:Influenza Vaccines; D022401:Meningococcal Vaccines